Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioLineRx Ltd

BLRX
Current price
1.52 USD +0.07 USD (+4.83%)
Last closed 1.45 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 109 769 392 USD
Yield for 12 month +109.08 %
Week
Month
Year
BLRX
21.11.2021 - 28.11.2021

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel. Address: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

Analytics

WallStreet Target Price

14.3 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures BLRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -38 930 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -36.73 %
PEG Ratio 0.2
Return On Equity TTM -152.82 %
Wall Street Target Price 14.3 USD
Revenue TTM
Book Value 0.014 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -0.75 USD
Diluted Eps TTM -0.75 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BLRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BLRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 15.07.2019
Dividend Date 15.07.2019

Stock Valuation BLRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -1.9784
Price Book MRQ 8.3577

Financials BLRX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BLRX

For 52 weeks

0.55 USD 2.53 USD
50 Day MA 1.56 USD
Shares Short Prior Month 490 595
200 Day MA 1.39 USD
Short Ratio 0.97
Shares Short 357 261
Short Percent 0.45 %